Biotechnology company Convergent Therapeutics will present a prostate cancer research findings at the American Society of Clinical Oncology (ASCO) annual meeting, June 2 to 6 in Chicago.
The research will describe the company's CONV01-α (actinium-225 J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225. It will be presented June 3 by Dr. Scott Tagawa from Weill Cornell Medicine and will also be available on demand.
